Patents Assigned to Pfizer Inc.
  • Antibodies specific for FLT3 and their uses
    Patent number: 11421040
    Abstract: The present invention provides antibodies that specifically bind to FLT3 (Fms-Like Tyrosine Kinase 3). The invention further provides bispecific antibodies that bind to FLT3 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of FLT3-mediated pathologies, including cancer such as Acute Myeloid Leukemia (AML).
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: August 23, 2022
    Assignee: Pfizer Inc.
    Inventors: Danielle Elizabeth Dettling, Yik Andy Yeung, Kristian Todd Poulsen, Veena Krishnamoorthy, Cesar Adolfo Sommer
  • Nitrile-Containing Antiviral Compounds
    Publication number: 20220257563
    Abstract: The invention relates to compounds of Formula I? wherein R, R1, R2, R3, p, q and q? are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.
    Type: Application
    Filed: April 22, 2022
    Publication date: August 18, 2022
    Applicant: Pfizer Inc.
    Inventors: Dafydd Rhys Owen, Matthew Richard Reese, Matthew Forrest Sammons, Jamison Bryce Tuttle, Patrick Robert Verhoest, Qingyi Yang
  • Immunogenic compositions for use in pneumococcal vaccines
    Patent number: 11413344
    Abstract: An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 18, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: August 16, 2022
    Assignee: Pfizer Inc.
    Inventors: David Cooper, Kathrin Ute Jansen, Michael William Pride
  • COMBINATION THERAPIES USING CDK INHIBITORS
    Publication number: 20220235141
    Abstract: This invention relates to a method for treating cancer by administering a CDK4/6 inhibitor or CDK2/4/6 inhibitor in combination with a 4-1BB agonist and/or an OX40 agonist to a subject in need thereof.
    Type: Application
    Filed: May 21, 2020
    Publication date: July 28, 2022
    Applicant: Pfizer Inc.
    Inventors: Stephen George Dann, Cecilia Marianne Oderup, Shahram Salek-Ardakani
  • Chimeric antigen receptors targeting CD70
    Patent number: 11396551
    Abstract: The disclosure provides CARs (CARs) that specifically bind to CD70. The disclosure further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The disclosure further relates to therapeutic methods for use of these CARs and engineered immune cells comprising these CARs for the treatment of a condition associated with malignant cells expressing CD70 (e.g., cancer).
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: July 26, 2022
    Assignee: Pfizer Inc.
    Inventors: Surabhi Srivatsa Srinivasan, Niranjana Aditi Nagarajan, Siler Panowski, Yoon Park, Tao Sai, Barbra Johnson Sasu, Thomas John Van Blarcom, Mathilde Brunnhilde Dusseaux, Roman Ariel Galetto
  • CDK2/4/6 inhibitors
    Patent number: 11396512
    Abstract: This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R2, R2A, R2B, R3, R4, R5A, R5B, R6, R7, R8, R9, p, q and r are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
    Type: Grant
    Filed: August 27, 2020
    Date of Patent: July 26, 2022
    Assignee: Pfizer Inc.
    Inventors: Douglas Carl Behenna, Ping Chen, Kevin Daniel Freeman-Cook, Robert Louis Hoffman, Mehran Jalaie, Asako Nagata, Sajiv Krishnan Nair, Sacha Ninkovic, Martha Alicia Ornelas, Cynthia Louise Palmer, Eugene Yuanjin Rui
  • 6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands
    Patent number: 11390623
    Abstract: The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R5, a and A are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D3-mediated (or D3-associated) disorders including, e.g., substance addiction, substance abuse, schizophrenia (e.g., its cognitive symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD or PD), Parkinson's disease, mania, anxiety, impulse control disorders, sexual disorders and depression.
    Type: Grant
    Filed: January 23, 2020
    Date of Patent: July 19, 2022
    Assignee: PFIZER INC.
    Inventors: Thomas Allen Chappie, Jaclyn Louise Henderson, Joseph Michael Young, Travis T. Wager, Bethany Lyn Kormos, Nandini Chaturbhai Patel, Simone Sciabola, Jamison Bryce Tuttle, Patrick Robert Verhoest, Joseph Walter Tucker
  • METABOLITES OF GLP1R AGONISTS
    Publication number: 20220213072
    Abstract: The present invention provides compounds of Formula XA-1, XA-2, XA-3, XA-4, XA-5, or XA-6, or metabolites of Compound 1 or metabolites of a compound of Formula I, PA-I, or PA-III, including compositions and salts thereof, which are useful in the prevention and/or treatment of a disease or disorder such as T2DM, obesity, or NASH, as well as analytical methods related to the administration of Compound 1 or a compound of Formula I, PA-1, or PA-III.
    Type: Application
    Filed: December 9, 2021
    Publication date: July 7, 2022
    Applicant: Pfizer Inc.
    Inventors: Andrew John Bessire, David James Edmonds, David Andrew Griffith, Amit Sumant Kalgutkar, Timothy Frank Ryder
  • Antibodies specific for CD70 and their uses
    Patent number: 11377500
    Abstract: The present invention provides antibodies that specifically bind to CD70 (Cluster of Differentiation 70). The invention further provides bispecific antibodies that bind to CD70 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of CD70-mediated pathologies, including cancer.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: July 5, 2022
    Assignee: Pfizer Inc.
    Inventors: Siler Panowski, Tao Sai, Barbra Johnson Sasu, Surabhi Srivatsa Srinivasan, Thomas John Van Blarcom
  • E. COLI FIMH MUTANTS AND USES THEREOF
    Publication number: 20220202923
    Abstract: This disclosure relates to the design of E. coli mutated FimH polypeptides that result in improved biochemical properties and immunogenicity, compositions comprising such polypeptides, and uses thereof.
    Type: Application
    Filed: December 17, 2021
    Publication date: June 30, 2022
    Applicant: Pfizer Inc.
    Inventors: Ye Che, Laurent Oliver Chorro, Robert George Konrad Donald, Matthew Curtis Griffor, Natalie Clare Silmon de Monerri
  • METABOLITES OF GLP1R AGONISTS
    Publication number: 20220193063
    Abstract: The present invention provides metabolites of Compound 1 or a compound of Formula I or III, including compositions and salts thereof, which are useful in the prevention and/or treatment of a disease or disorder such as T2DM, obesity, or NASH, as well as analytical methods related to the administration of Compound 1 or a compound of Formula I or III.
    Type: Application
    Filed: December 9, 2021
    Publication date: June 23, 2022
    Applicant: Pfizer Inc.
    Inventors: Andrew John Bessire, David James Edmonds, David Andrew Griffith, Amit Sumant Kalgutkar
  • Anti-ROBO2 antibodies, compositions, methods and uses thereof
    Patent number: 11365253
    Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to ROBO2, as well as uses, and methods thereof.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: June 21, 2022
    Assignees: Pfizer Inc., Boston Medical Center Corporation
    Inventors: Stephen Berasi, Janet Elizabeth Buhlmann, Eric M. Bennett, Nathan Higginson-Scott, Huilan Gao, Zong Sean Juo, Stefano V. Gulla, Christine Huard, Sreekumar R. Kodangattil, Jian Li, Weining Lu, Xueping Fan, David J. Salant
  • Bifunctional cytotoxic agents containing the CTI pharmacophore
    Patent number: 11365263
    Abstract: The present invention is directed to novel bifunctional CTI-CTI and CBI-CTI dimers of the formula: F1-L1-T-L2-F2 where F1, L1, T, L2 and F2 are as defined herein, useful for the treatment for proliferative diseases, where the inventive dimers can function as stand-alone drugs, payloads in antibody-drug-conjugates (ADCs), and linker-payload compounds useful in connection with the production or administration of such ADCs; and to compositions including the aforementioned dimers, linker-payloads and ADCs, and methods for using these dimers, linker-payloads and ADCs, to treat pathological conditions including cancer.
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: June 21, 2022
    Assignee: PFIZER INC.
    Inventors: Andreas Maderna, Chakrapani Subramanyam, Lawrence N. Tumey, Zecheng Chen, Jeffrey M. Casavant
  • Cysteine engineered antibody drug conjugates
    Patent number: 11364303
    Abstract: The invention relates to polypeptides, antibodies, and antigen-binding fragments thereof, that comprise an engineered cysteine for site-specific conjugation.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: June 21, 2022
    Assignee: Pfizer Inc.
    Inventors: Madan Katragadda, Russell Dushin, Lawrence Nathan Tumey
  • (AZA)Benzothiazolyl Substituted Pyrazole Compounds
    Publication number: 20220184041
    Abstract: This application includes a compound of Formula I or a pharmaceutically acceptable salt thereof; wherein the variables R1a, R1b, R2, R3, X, Y and Z are as defined herein, pharmaceutical compositions comprising the compounds of Formula I and methods of treatment comprising administering to a patient in need thereof a compound of Formula I for the treatment of transthyretin amyloidosis and diseases related thereto.
    Type: Application
    Filed: November 23, 2021
    Publication date: June 16, 2022
    Applicant: Pfizer Inc.
    Inventors: Shawn Cabral, Daniel Paul Canterbury, Robert Lee Dow, Andrew Fensome, Magdalena Korczynska, Sophie Yvette Lavergne, Allyn Timothy Londregan, Vincent Mascitti, David Walter Piotrowski, Andre Shavnya, Meihua Mike Tu, Tao Wang, Hanna Maria Wisniewska
  • Anti-AVB8 antibodies and compositions and uses thereof
    Patent number: 11359024
    Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to ?v?8 integrin. The invention includes uses, and associated methods of using the antibodies.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: June 14, 2022
    Assignees: PFIZER INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Kyle Steven Niessen, Dharmaraj Samuel, Charles Ray Holst, Matthew Ross Drever, Dean Sheppard, Rosemary J. Akhurst, Amha Atakilit, Dominique Meyer, Isaac J. Rondon, Joseph Dal Porto
  • Nitrile-containing antiviral compounds
    Patent number: 11351149
    Abstract: The invention relates to compounds of Formula I? wherein R, R1, R2, R3, p, q and q? are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.
    Type: Grant
    Filed: August 5, 2021
    Date of Patent: June 7, 2022
    Assignee: Pfizer Inc.
    Inventors: Dafydd Rhys Owen, Martin Youngjin Pettersson, Matthew Richard Reese, Matthew Forrest Sammons, Jamison Bryce Tuttle, Patrick Robert Verhoest, Liuqing Wei, Qingyi Yang, Xiaojing Yang
  • ESCHERICHIA COLI COMPOSITIONS AND METHODS THEREOF
    Publication number: 20220168410
    Abstract: In one aspect, the invention relates to an immunogenic composition comprising modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof. Multivalent vaccines may be prepared by combining two or more monovalent immunogenic compositions for different E. coli serotypes. In one embodiment, the modified O-polysaccharide molecules are produced by a recombinant bacterium that includes a wzz gene.
    Type: Application
    Filed: February 15, 2022
    Publication date: June 2, 2022
    Applicant: Pfizer Inc.
    Inventors: Robert G.K. Donald, Annaliesa Sybil Anderson, Laurent Oliver Chorro, Jianxin Gu, Jin-Hwan Kim, Srinivas Kodali, Jason Arnold Lotvin, Justin Keith Moran, Rosalind Pan, Avvari Krishna Prasad, Mark Edward Ruppen, Suddham Singh, Ling Chu, Scott Ellis Lomberk, Karen Kiyoko Takane, Nishith Merchant, Wei Chen
  • TIME TO RESOLUTION OF AXITINIB-RELATED ADVERSE EVENTS
    Publication number: 20220168293
    Abstract: This invention relates to a method of managing an adverse event in a renal cell carcinoma (RCC) patient undergoing treatment with axitinib, or a pharmaceutically acceptable salt thereof, wherein said method comprises interrupting axitinib, or a pharmaceutically acceptable salt thereof, treatment for at least 1-7 days to allow the adverse event to resolve before restarting treatment. Additionally, the invention relates to a method of managing an adverse event in an RCC patient undergoing treatment with a combination of axitinib, or a pharmaceutically acceptable salt thereof, and an immune-oncology (IO) agent, wherein said method comprises interrupting axitinib, or a pharmaceutically acceptable salt thereof, treatment for at least 4-11 days to allow the adverse event to resolve before restarting axitinib, or a pharmaceutically acceptable salt thereof, treatment.
    Type: Application
    Filed: November 30, 2021
    Publication date: June 2, 2022
    Applicant: PFIZER INC.
    Inventor: Despoina Thomaidou
  • Toll-like receptor agonists
    Patent number: 11339159
    Abstract: The present invention relates to imidazo-pyridinyl compounds, or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject.
    Type: Grant
    Filed: July 13, 2020
    Date of Patent: May 24, 2022
    Assignee: Pfizer Inc.
    Inventors: Omar Ahmad, Andrew Fensome, Erik Alphie LaChapelle, Ethan Lawrence Fisher, Rayomand J. Unwalla, Jun Xiao, Lei Zhang